(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued
(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. … Continued
(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately … Continued
(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants have been awarded to twenty top scientists at thirteen leading medical centers across the country. “Our 2017 grantees are among the best and brightest working … Continued
(Dec. 21, 2016) Research published recently in Cancer Discovery suggests that cells in the fallopian tube previously thought to be precursors to high grade serous ovarian cancer may sometimes be cells that have metastasized and implanted into the fallopian tube. The research was conducted by a team at the University of Chicago under the guidance … Continued
(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone. The approval is based on two large Phase III … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued
(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research and published studies, there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a … Continued
Get email updates about research news, action alerts, and ways to join the fight.
